Uncategorized

Deciphex, a leader in AI-powered digital pathology, today announced the execution of a new €15 million investment from  Claret Capital Partners, Europe's largest independent growth debt fund manager. This strategic financing will accelerate Deciphex's expansion in the United States and support the company's ambition to become the leading provider of histopathology reporting services in the UK by 2027. Read More

NovaUCD-based medtech OncoAssure has announced the launch of its OncoAssure Prostate Test in the US market, as well as plans to hold an investment round last year. The next-generation prognostic test is designed to support clinical decision-making for men diagnosed with localised prostate cancer, and helps to assess the risk of aggressive disease and disease recurrence. Read More

Cinclus Pharma Holding, a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of gastric acid-related diseases, has announced an agreement with Zentiva, a European pharmaceutical company, for the commercialisation and manufacturing of its lead asset, linaprazan glurate, in Europe. Read More

Signum Surgical, the medical technology company developing innovative solutions to treat colorectal diseases, is pleased to announce the appointment of Ms. Carol Burns as Chief Executive Officer. Ms. Burns’ appointment is a pivotal milestone for Signum, as the Company initiates commercialization of BioHealx, a first-of-its-kind medical device for the treatment of anal fistula, a painful and debilitating colorectal condition that affects one in 5,000 people worldwide. Read More

Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced that the Company’s Co-Founder and Chief Scientific Officer, Dr. Steven Stice, has been inducted into the 2025 Class of the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. Read More

Sigrid Therapeutics (Sigrid) is excited to announce that it has secured U.S. market access for its proprietary SiPore® technology, following the success of the SHINE study, the largest of its kind in prediabetes. The study demonstrated that Carb Fence™, an medical-grade, fast-acting liquid formula powered by SiPore®, effectively reduces long-term blood sugar levels HbA1c (A1C), improves glucose metabolism, and reduces body weight - while preserving muscle mass. These robust findings position Carb Fence™ as a pioneering medical food in the U.S., a category recognized by the FDA for the dietary management of diseases or conditions under physician supervision, as defined [...]

Bounce Insights, an Irish startup specialising in AI-powered market research, has announced a €4.2 million funding round. This funding will fuel the company’s expansion into the US market, including the opening of a New York office to support its 25-person team and plans to triple its headcount globally by the end of 2026. Read more

South Indian dairy company MilkyMist has teamed up with SIG and AnaBio Technologies to introduce what is claimed to be the world’s first long-life probiotic buttermilk in aseptic carton packs. The ground-breaking development, showcased at Gulfood Manufacturing 2024 in Dubai, represents a major breakthrough in the beverage industry, allowing probiotics to be incorporated into shelf-stable drinks in aseptic cartons for the first time. Read Article Here

Swedish clinical-stage drug developer Cinclus Pharma (STO: CINPHA), a specialist in treatments for gastric acid-related diseases, had picked up Chinese approval for linaprazan glurate. The outcome represents the firm’s first marketing approval in China. The approval by the National Medical Products Administration (NMPA) paves the way for commercialization in the People’s Republic of China in 2025. Read Article Here

Galway MedTech company SymPhysis Medical has secured €2.2m funding for the development of a device to address the condition of fluid in the chest of cancer patients. The medtech company will seek regulatory approval in the US for its device treating end-of-life cancer patients at the end of 2025. Business Post Article